Tradestie Institutional Equity Comparison Engine

CGON vs FDMT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGON Overall Edge

CGON Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Momentum & Technical, Options & Structure while FDMT counters with relative strength in Growth & Margin. Fundamentally, CGON trades at N/M Forward P/E with -4293.5% operating margin (-3.7% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CGON N/M vs FDMT N/M Fwd P/E
Growth & Margin Winner FDMT
Op Margin -4293.5% vs -222.7% ยท YoY -3.7% vs +4505.6%
Momentum & Technical Winner CGON
1Y +124.9% vs +11.0% ยท 52W Pos 84% vs 45%
Options & Structure Winner CGON
CONSOLIDATION (85th %ile IV) vs BREAKDOWN (10th %ile IV)
CGON NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.16% 1D
Market Cap $6.3B
1M Return +41.91%
1Y Return +124.93%
Forward P/E N/M
Unified AI Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.41
-6.7% 1D
Market Cap $669.3M
1M Return -6.01%
1Y Return +10.99%
Forward P/E N/M
Unified AI Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGON +124.93% FDMT +10.99% Spread: +113.94 pp (CGON Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CGON Revenue FDMT Revenue CGON Op. Margin FDMT Op. Margin Margin Edge
FY2019 N/A $10M N/A -729.4% FDMT
FY2020 N/A $10M N/A -424.0% FDMT
FY2021 N/A $20M N/A -395.5% FDMT
FY2022 N/A $0M N/A -3516.5% FDMT
FY2023 $0M $20M -27180.9% -544.6% FDMT
FY2024 $0M $0M -10067.3% -507678.4% CGON
FY2025 $0M $90M -4722.1% -187.2% FDMT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGON (5) vs FDMT (3)
Institutional Metric CGON FDMT Criterion Row Winner
Market Capitalization Scale $6.3B $669.3M Larger Scale CGON
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -3.7% +4505.6% Higher Growth FDMT
Operating Margin (TTM) Profitability -4293.5% -222.7% Higher Margin FDMT
Net Profit Margin Profitability 0.0% -208.6% Higher Margin CGON
Return on Equity (ROE) Capital Efficiency -28.3% -56.7% Higher ROE CGON
52-Week Range Position Momentum 84% ($37โ€“$94) 45% ($7โ€“$17) Stronger Trend CGON
Beta / 30D Volatility Risk Regime 0.77ฮฒ ยท 86% Vol 1.90ฮฒ ยท 91% Vol Lower Realized Risk CGON
Unified Institutional Score Composite Signal 45.0 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite FDMT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGON vs FDMT Buy Guide
CGON CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 85th %ile
IV Regime Extreme (>80th %ile)
Live CGON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGON nor FDMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.